Thus, AH-1 could be a powerful agent for alternative therapeutic agent for rickets patients with VDR(R274L) mutation, as supraphysiological doses of current vitamin D-dependent therapeutic approaches such as 1,25(OH)2D3 treatment, have limited success5,6. Here, VDR is linked to rickets.